The Thomson Corporation has announced that it has completed the acquisition of Centre for Medicines Research International (CMR), a provider of R&D performance metrics to the global pharmaceutical industry. Financial terms of the transaction were not disclosed. Separately, the CMR International Institute for Regulatory Science serves the pharmaceutical and biotech markets by addressing regulatory affairs and their scientific basis through an independent advisory board. The "Institute" will continue to be supported in its current manner. CMR's leadership, including founder Professor Stuart Walker and CEO Peter Joshua, as well as the company's employees, will become part of Thomson Scientific.